Fieke W. Hoff

592 total citations
49 papers, 215 citations indexed

About

Fieke W. Hoff is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Fieke W. Hoff has authored 49 papers receiving a total of 215 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hematology, 29 papers in Molecular Biology and 10 papers in Genetics. Recurrent topics in Fieke W. Hoff's work include Acute Myeloid Leukemia Research (22 papers), Protein Degradation and Inhibitors (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Fieke W. Hoff is often cited by papers focused on Acute Myeloid Leukemia Research (22 papers), Protein Degradation and Inhibitors (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Fieke W. Hoff collaborates with scholars based in United States, Netherlands and Australia. Fieke W. Hoff's co-authors include Steven M. Kornblau, Terzah M. Horton, Eveline S.J.M. de Bont, Yihua Qiu, Amina A. Qutub, Chenyue W. Hu, Yazan F. Madanat, Suk-Young Yoo, E. Anders Kolb and Elias Jabbour and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Fieke W. Hoff

43 papers receiving 211 citations

Peers

Fieke W. Hoff

HEMAT

ONCOL

GENET

Cyril Quivoron France

E. Loraine Karran United Kingdom

Marcos J. Ruiz United States

Jeffrey Strovel United States

Emanuela Ferrari Italy

Jevon Cutler United States

Eugene Hwang United States

Anjali Cremer Germany

Jiro Minami Japan

Cyril Quivoron France

Fieke W. Hoff

119 ×0.8

82 ×0.8

HEMAT

28 ×0.8

ONCOL

51 ×1.5

GENET

52 ×2.2

Citations per year, relative to Fieke W. Hoff Fieke W. Hoff (= 1×) peers Cyril Quivoron

Countries citing papers authored by Fieke W. Hoff

Since Specialization

Citations

This map shows the geographic impact of Fieke W. Hoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fieke W. Hoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fieke W. Hoff more than expected).

Fields of papers citing papers by Fieke W. Hoff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fieke W. Hoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fieke W. Hoff. The network helps show where Fieke W. Hoff may publish in the future.

Co-authorship network of co-authors of Fieke W. Hoff

This figure shows the co-authorship network connecting the top 25 collaborators of Fieke W. Hoff. A scholar is included among the top collaborators of Fieke W. Hoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fieke W. Hoff. Fieke W. Hoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hoff, Fieke W., Eduard Schulz, Steven Z. Pavletic, & Alain Mina. (2025). Iron chelation therapy in myelodysplastic syndromes and allogeneic hematopoietic cell transplantation, a delicate balance. Blood Reviews. 74. 101319–101319.

Hoff, Fieke W., Olga K. Weinberg, Robert H. Collins, et al.. (2025). Imatinib-Induced Clinical Response in ETV6::ACSL6 Myeloid Neoplasm with Eosinophilic Pneumonitis: A Case Report. American Journal of Case Reports. 26. e946517–e946517.

Hoff, Fieke W., Stephen S. Chung, Amer M. Zeidan, & Yazan F. Madanat. (2025). Management of Anemia in Lower-Risk Myelodysplastic Syndromes/Neoplasms With Novel Agents. JCO Oncology Practice. OP2400910–OP2400910.

Hoff, Fieke W., Chao Xing, & Abhimanyu Garg. (2024). A Novel Subtype of Acquired Generalized Lipodystrophy Associated With Subcutaneous Panniculitis-Like T-cell Lymphoma. JCEM Case Reports. 2(5). luae069–luae069. 2 indexed citations

Hoff, Fieke W., Yihua Qiu, David T. Teachey, et al.. (2024). The Proteomics of T-Cell and Early T-Cell Precursor (ETP) Acute Lymphocytic Leukemia: Prognostic Patterns in Adult and Pediatric-ETP ALL. Cancers. 16(24). 4241–4241.

Hoff, Fieke W., Rahul Banerjee, Georgia McCaughan, et al.. (2024). Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis. Blood Cancer Journal. 14(1). 52–52. 9 indexed citations

Hübner, Stefan, Fieke W. Hoff, Brandon D. Brown, et al.. (2023). DNA Damage Response−Related Proteins Are Prognostic for Outcome in Both Adult and Pediatric Acute Myelogenous Leukemia Patients: Samples from Adults and from Children Enrolled in a Children’s Oncology Group Study. International Journal of Molecular Sciences. 24(6). 5898–5898. 3 indexed citations

Hoff, Fieke W. & Yazan F. Madanat. (2023). Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance. Cells. 12(4). 627–627. 3 indexed citations

Khan, Adeel, Urvashi Pandey, Fieke W. Hoff, et al.. (2023). Shattering myths regarding Hispanic ethnicity and survival in acute myeloid leukemia: Insights from the National Cancer Database.. Journal of Clinical Oncology. 41(16_suppl). 7032–7032.

10.

Hoff, Fieke W., Stephen S. Chung, Prapti A. Patel, et al.. (2023). Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience. Transplant Immunology. 77. 101808–101808.

11.

Hoff, Fieke W., Yihua Qiu, James W. Lillard, et al.. (2022). Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets. Blood Cancer Journal. 12(3). 43–43. 8 indexed citations

12.

Hoff, Fieke W., Yihua Qiu, Chenyue W. Hu, et al.. (2022). Clinical relevance of proteomic profiling in <i>de novo</i> pediatric acute myeloid leukemia: a Children’s Oncology Group study. Haematologica. 107(10). 2329–2343. 8 indexed citations

13.

Butler, Miriam, Dorette S. van Ingen Schenau, Jiangyan Yu, et al.. (2021). BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway. Blood. 138(23). 2383–2395. 17 indexed citations

14.

Qiu, Yihua, Fieke W. Hoff, Peter P. Ruvolo, et al.. (2021). RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia. 36(3). 712–722. 3 indexed citations

15.

Chae, Hee-Don, Fieke W. Hoff, Benedetta Accordi, et al.. (2020). RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit. Oncotarget. 11(25). 2387–2403. 17 indexed citations

16.

Hoff, Fieke W., Yiling Lu, & Steven M. Kornblau. (2019). Antibody Screening. Advances in experimental medicine and biology. 1188. 149–163. 1 indexed citations

17.

Hoff, Fieke W., Chenyue W. Hu, Yihua Qiu, et al.. (2018). Recognition of Recurrent Protein Expression Patterns in Pediatric Acute Myeloid Leukemia Identified New Therapeutic Targets. Molecular Cancer Research. 16(8). 1275–1286. 14 indexed citations

18.

Hoff, Fieke W., Chenyue W. Hu, Yihua Qiu, et al.. (2018). Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance. Molecular Cancer Research. 16(8). 1263–1274. 11 indexed citations

19.

Hoff, Fieke W., Chenyue W. Hu, Amina A. Qutub, et al.. (2018). Mycoplasma contamination of leukemic cell lines alters protein expression determined by reverse phase protein arrays. Cytotechnology. 70(6). 1529–1535. 6 indexed citations

20.

Hoff, Fieke W., et al.. (2017). Optimizing VAP scars after childhood cancer treatment: a pilot study. Supportive Care in Cancer. 25(12). 3651–3654. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact